Adjunctive Glucocorticoid Therapy in Patients with Septic Shock
Source: View publication →
In patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not reduce 90-day mortality compared to placebo, although it led to faster resolution of shock and earlier liberation from mechanical ventilation.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ADRENAL trial provided definitive, large-scale evidence that isolated hydrocortisone therapy is not a mortality-reducing intervention in severe septic shock. However, it conclusively demonstrated that hydrocortisone safely accelerates hemodynamic stabilization, shortens time on the ventilator, and reduces ICU length of stay. Consequently, modern critical care guidelines position corticosteroids as an adjunctive therapy to rapidly reverse shock and reduce the duration of vasopressor support in catecholamine-refractory patients, rather than as a primary life-saving measure.
Historical Context
The use of corticosteroids in septic shock has been one of the most heavily debated topics in critical care for decades. Early trials in the 1980s using high-dose steroids were abandoned due to a lack of efficacy and increased secondary infections. In 2002, Annane et al. revitalized interest by demonstrating a mortality benefit with low-dose hydrocortisone plus fludrocortisone in non-responders to an ACTH stimulation test. However, the 2008 CORTICUS trial (which used hydrocortisone alone and enrolled less severely ill patients) failed to show a survival benefit, leading to widespread clinical equipoise. Published concurrently with the APROCCHSS trial in 2018, the ADRENAL trial represented the largest study to date addressing this question. While APROCCHSS validated combination therapy (hydrocortisone + fludrocortisone), ADRENAL conclusively demonstrated the systemic, non-mortality benefits of hydrocortisone alone in a mechanically ventilated cohort.
Guided Discussion
High-yield insights from every perspective
How does the physiologic mechanism of endogenous cortisol explain the ADRENAL trial's secondary findings of faster shock resolution and earlier extubation in patients receiving hydrocortisone?
Key Response
Cortisol upregulates alpha-1 adrenergic receptors on vascular smooth muscle, enhancing the body's responsiveness to endogenous and exogenous catecholamines, which explains the faster resolution of shock. Additionally, its potent anti-inflammatory effects reduce systemic and airway inflammation, helping to improve lung compliance and facilitate earlier liberation from mechanical ventilation.
Given that hydrocortisone in the ADRENAL trial did not improve 90-day mortality but did reduce the duration of shock and time on the ventilator, what specific clinical thresholds should prompt you to initiate hydrocortisone in a patient with septic shock?
Key Response
While it doesn't offer a mortality benefit, hydrocortisone is utilized to reduce morbidity and the toxicities associated with high-dose vasopressors. Residents should recognize that steroids are typically initiated when patients have refractory shock, defined by escalating or high-dose vasopressor requirements (e.g., norepinephrine > 0.25 mcg/kg/min) despite adequate fluid resuscitation, aiming to reverse shock faster and prevent ischemic complications.
The ADRENAL trial utilized a continuous infusion of hydrocortisone, while the concurrently published APROCCHSS trial used intermittent boluses of hydrocortisone combined with fludrocortisone and found a mortality benefit. How might these differences in administration and the addition of a mineralocorticoid explain the divergent mortality outcomes?
Key Response
Continuous infusion in ADRENAL minimizes glycemic variability compared to bolus dosing, but the APROCCHSS trial's inclusion of fludrocortisone suggests that robust mineralocorticoid receptor activation may be the critical driver of the mortality benefit seen in that trial. Fellows must synthesize these trials to understand how varied pharmacodynamic profiles (pure glucocorticoid vs. mixed glucocorticoid/mineralocorticoid effects) impact sepsis survival.
When leading family meetings for patients in refractory septic shock, how do you integrate the ADRENAL trial's findings to set realistic expectations about the initiation of corticosteroids?
Key Response
Attendings must navigate complex data translation. The rationale is to frame corticosteroids not as a definitive life-saving intervention (given the lack of 90-day mortality benefit), but as an adjunctive measure that 'buys time' by stabilizing blood pressure, reducing the need for tissue-damaging doses of pressors, and potentially shortening the ICU stay, while balancing this against risks like hyperglycemia.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ADRENAL trial enrolled a broad, heterogeneous population of over 3,800 patients to power its 90-day mortality outcome. How might the inclusion of 'all-comers' with septic shock obscure the detection of a heterogeneous treatment effect (HTE), and what alternative trial designs could better identify steroid-responsive endotypes?
Key Response
Sepsis is a highly heterogeneous syndrome with distinct transcriptomic endotypes (e.g., hyper-inflammatory vs. immunosuppressed). A PhD-level critique recognizes that testing an immunomodulator in an unselected population biases the results toward the null. Future research should utilize predictive enrichment strategies or biomarker-guided adaptive platform trials (like REMAP-CAP) to isolate phenotypes that genuinely benefit from glucocorticoids.
A significant methodological challenge in pragmatic critical care trials like ADRENAL is the rate of open-label crossover. How does the administration of systemic corticosteroids to patients in the placebo group threaten the trial's internal validity, and what statistical safeguards are necessary during peer review?
Key Response
Crossover to open-label steroids in the placebo arm creates treatment contamination that biases the study findings toward the null, potentially masking a true mortality benefit. Editors would demand rigorous reporting of the crossover rate, the specific indications for open-label use, and robust per-protocol and as-treated sensitivity analyses to ensure the negative primary outcome is not simply an artifact of contamination.
In light of the discordant mortality outcomes between the ADRENAL and APROCCHSS trials, how should the Surviving Sepsis Campaign (SSC) guidelines grade the recommendation for corticosteroid use in septic shock, and what specific clinical triggers should be codified?
Key Response
The SSC guidelines currently issue a weak recommendation with moderate-quality evidence for using IV corticosteroids in patients with septic shock who have an ongoing requirement for vasopressor therapy. The committee must integrate ADRENAL's neutral mortality but positive shock-reversal data with APROCCHSS's positive mortality data, maintaining the recommendation to utilize steroids primarily to hasten shock resolution in refractory cases, while explicitly defining 'refractory' (e.g., continuous requirement of norepinephrine at or above 0.25 mcg/kg/min).
Clinical Landscape
Noteworthy Related Trials
Annane Trial
Tested
Hydrocortisone 50mg q6h + Fludrocortisone 50mcg daily for 7 days
Population
Patients with septic shock requiring mechanical ventilation and vasopressors
Comparator
Placebo
Endpoint
28-day survival in nonresponders to corticotropin
CORTICUS Trial
Tested
Hydrocortisone 50mg q6h for 5 days then tapered
Population
Adults with septic shock
Comparator
Placebo
Endpoint
28-day mortality in nonresponders to corticotropin
APROCCHSS Trial
Tested
Hydrocortisone 50mg q6h + Fludrocortisone 50mcg daily
Population
Adult patients with septic shock
Comparator
Placebo
Endpoint
90-day all-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis